search
Back to results

Local Consolidative Therapy in Colorectal Cancer

Primary Purpose

Colorectal Cancer Metastatic

Status
Withdrawn
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Local consolidative therapy
Sponsored by
Fox Chase Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer Metastatic focused on measuring oligometastatic, colorectal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects must have histologically or cytologically confirmed metastatic colorectal cancer with 1-3 active metastatic lesions irrespective of location. Previously locally treated (e.g. radiation or interventional radiology-based ablated) metastases that have had a 6-month progression free interval per imaging exams, do not count toward the 1-3 active metastases. Adjacent lymph nodes in the same region constitute one active lesion.
  • Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 12.0.
  • All sites of metastatic disease must be amenable to either surgical resection or stereotactic body radiotherapy (SBRT).
  • The primary lesion may be either intact or previously resected, but if intact must be resected as part of LCT (primary does not count as one of 1-3 sites of metastatic disease).
  • Subjects must have received at least one prior line of systemic therapy with a fluoropyrimidine-based regimen for metastatic disease and be candidates for further systemic chemotherapy. Front-line therapy could have been discontinued for disease progression, unacceptable toxicity, or drug holiday, provided that the therapy was discontinued less than six months from study enrollment.
  • Age > 18 years.
  • ECOG performance status 0 or 1

  • Subjects must have normal organ and marrow function as defined below

    • Absolute neutrophil count > 1,500/mcL
    • Platelets > 100,000/mcL
    • Total bilirubin < 2 mg/dL
    • AST/ALT (SGOT/SGPT) < 5X ULN
    • Creatinine < 1.5X ULN OR
    • Creatinine clearance < 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal
  • Subjects must possess the ability to understand and willingness to sign a written informed consent and HIPAA consent document.

Exclusion Criteria:

  • Subjects must not be experiencing toxicity due to prior therapy that has not resolved to ≤Grade 1 by study registration, with the exception of sensory neuropathy related to previous oxaliplatin exposure, alopecia and fatigue.
  • >Grade 2 sensory neuropathy
  • Subjects must not be receiving any other investigational agents.
  • Subjects must not have known central nervous system (CNS) metastases and/or carcinomatous meningitis, either untreated or treated.
  • Subjects must not be unfit to receive combination therapy (>/=2 drugs that could include one biologic agent) as determined by the treating physician.
  • Subjects must be able to undergo surgical resection and/or SBRT.
  • Subjects must not have 4 or more active metastatic sites.
  • Subjects must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Any condition or significant co-morbidity that prevents safe surgery or delivery of SBRT
  • Subjects must not be pregnant or breast feeding. Refer to section 4.4 for further detail.

Sites / Locations

  • Fox Chase Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Local consolidative therapy (LCT) + systemic therapy

Systemic therapy alone

Arm Description

Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies

Appropriate second-line systemic therapy, as defined in the NCCN guidelines will be used during study treatment (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). The choice of specific regimen will be left to the discretion of the treating oncologist but cannot include other experimental or investigational treatment. Sample appropriate systemic therapies include FOLFOX or FOLFIRI with a biologic agent such as an anti-angiogenic antibody or anti-EGFR antibody.

Outcomes

Primary Outcome Measures

Progression free survival
To assess the impact of local consolidative therapy (LCT) (surgical resection and/or radiotherapy) on the PFS of subjects with oligometastatic colorectal cancer undergoing second-line systemic therapy. PFS- defined as the duration of time from randomization to date of disease progression or death, whichever occurs first. Individuals who are alive and progression free at last follow-up will be considered censored at the time of last tumor assessment.

Secondary Outcome Measures

Overall suvival (OS)
To assess the impact of local consolidative therapy (LCT) (surgical resection and/or radiotherapy) on the overall survival (OS) of subjects with oligometastatic colorectal cancer undergoing second-line systemic therapy. • OS - defined as the duration of time from randomization to date of death. Individuals who are alive at last follow-up will be considered censored at the time of last contact.
Patient reported outcomes (PROs)
To assess patient reported outcomes (PROs) as measured by the EQ-5D-5L instrument. • PRO - defined as the score on the EQ-5D-5L questionnaire, this will be measured at baseline, and then 2 other times after treatment has begun

Full Information

First Posted
September 21, 2021
Last Updated
December 7, 2022
Sponsor
Fox Chase Cancer Center
Collaborators
Varian Medical Systems
search

1. Study Identification

Unique Protocol Identification Number
NCT05062720
Brief Title
Local Consolidative Therapy in Colorectal Cancer
Official Title
RT-167: Local Consolidative Therapy in Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Study is being closed due to lack of accrual
Study Start Date
July 29, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
October 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fox Chase Cancer Center
Collaborators
Varian Medical Systems

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase II randomized multisite trial to study the effect of a combination of local consolidative therapy with systemic therapy in subjects with oligometastatic colorectal cancer who have progressed on the first line of therapy.
Detailed Description
This is a Phase II randomized multisite trial to study the effect of a combination of local consolidative therapy with systemic therapy in subjects with oligometastatic colorectal cancer who have progressed on the first line of therapy. The primary objective of this study is progression free survival which is defined as time from randomization until disease progression is documented. Response will be evaluated by scans every 3 months (+/- 7 days). Subjects will continue systemic therapy for 6 months and then at the investigator's discretion, disease progression or unacceptable toxicity. Subjects who are not evaluable for the primary endpoint will be replaced. A total of 105 subjects will be randomized in 2:1 ratio into two cohorts that will receive a combination of LCT along with the systemic therapy or systemic therapy alone. Arm A: LCT + systemic therapy; 70 subjects will be accrued Arm B: Systemic therapy alone; 35 subjects will be accrued Systemic therapy will be second line chemotherapy as per NCCN guidelines with the choice of drugs at the treating physician's discretion. Crossover to LCT will be allowed at progression for subjects randomized to Arm B. The study will be opened at a total of 5 sites with a duration of 26 months of accrual and 10 additional months of follow-up, with a total of 36 months. The study will be conducted in 2 phases with an interim analysis conducted when 29 PFS events have been observed to assess futility/ feasibility of the study. Subjects will have the option of undergoing tumor biopsy and blood sampling before beginning treatment. A correlative study is proposed using the genomic risk group stratification proposed by Pitroda et al.[9] Collected blood will be analyzed at the conclusion of the trial, with the expectation of comparing levels of circulating tumor DNA between baseline and 3-month time-points between subjects in Arms A and B. As this technology is rapidly evolving, we are not specifying the technology that will be used and will use the most effective assay at the time of trial completion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer Metastatic
Keywords
oligometastatic, colorectal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Model Description
A total of 105 subjects will be randomized in 2:1 ratio into two cohorts that will receive a combination of LCT along with the systemic therapy or systemic therapy alone.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Local consolidative therapy (LCT) + systemic therapy
Arm Type
Experimental
Arm Description
Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
Arm Title
Systemic therapy alone
Arm Type
Active Comparator
Arm Description
Appropriate second-line systemic therapy, as defined in the NCCN guidelines will be used during study treatment (https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf). The choice of specific regimen will be left to the discretion of the treating oncologist but cannot include other experimental or investigational treatment. Sample appropriate systemic therapies include FOLFOX or FOLFIRI with a biologic agent such as an anti-angiogenic antibody or anti-EGFR antibody.
Intervention Type
Radiation
Intervention Name(s)
Local consolidative therapy
Intervention Description
Local Consolidative Therapy (LCT) will be defined as surgical resection or stereotactic body radiotherapy (SBRT) or a combination of both strategies
Primary Outcome Measure Information:
Title
Progression free survival
Description
To assess the impact of local consolidative therapy (LCT) (surgical resection and/or radiotherapy) on the PFS of subjects with oligometastatic colorectal cancer undergoing second-line systemic therapy. PFS- defined as the duration of time from randomization to date of disease progression or death, whichever occurs first. Individuals who are alive and progression free at last follow-up will be considered censored at the time of last tumor assessment.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Overall suvival (OS)
Description
To assess the impact of local consolidative therapy (LCT) (surgical resection and/or radiotherapy) on the overall survival (OS) of subjects with oligometastatic colorectal cancer undergoing second-line systemic therapy. • OS - defined as the duration of time from randomization to date of death. Individuals who are alive at last follow-up will be considered censored at the time of last contact.
Time Frame
6 months
Title
Patient reported outcomes (PROs)
Description
To assess patient reported outcomes (PROs) as measured by the EQ-5D-5L instrument. • PRO - defined as the score on the EQ-5D-5L questionnaire, this will be measured at baseline, and then 2 other times after treatment has begun
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must have histologically or cytologically confirmed metastatic colorectal cancer with 1-3 active metastatic lesions irrespective of location. Previously locally treated (e.g. radiation or interventional radiology-based ablated) metastases that have had a 6-month progression free interval per imaging exams, do not count toward the 1-3 active metastases. Adjacent lymph nodes in the same region constitute one active lesion. Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 as described in detail in section 12.0. All sites of metastatic disease must be amenable to either surgical resection or stereotactic body radiotherapy (SBRT). The primary lesion may be either intact or previously resected, but if intact must be resected as part of LCT (primary does not count as one of 1-3 sites of metastatic disease). Subjects must have received at least one prior line of systemic therapy with a fluoropyrimidine-based regimen for metastatic disease and be candidates for further systemic chemotherapy. Front-line therapy could have been discontinued for disease progression, unacceptable toxicity, or drug holiday, provided that the therapy was discontinued less than six months from study enrollment. Age > 18 years. ECOG performance status 0 or 1 Subjects must have normal organ and marrow function as defined below Absolute neutrophil count > 1,500/mcL Platelets > 100,000/mcL Total bilirubin < 2 mg/dL AST/ALT (SGOT/SGPT) < 5X ULN Creatinine < 1.5X ULN OR Creatinine clearance < 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal Subjects must possess the ability to understand and willingness to sign a written informed consent and HIPAA consent document. Exclusion Criteria: Subjects must not be experiencing toxicity due to prior therapy that has not resolved to ≤Grade 1 by study registration, with the exception of sensory neuropathy related to previous oxaliplatin exposure, alopecia and fatigue. >Grade 2 sensory neuropathy Subjects must not be receiving any other investigational agents. Subjects must not have known central nervous system (CNS) metastases and/or carcinomatous meningitis, either untreated or treated. Subjects must not be unfit to receive combination therapy (>/=2 drugs that could include one biologic agent) as determined by the treating physician. Subjects must be able to undergo surgical resection and/or SBRT. Subjects must not have 4 or more active metastatic sites. Subjects must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Any condition or significant co-morbidity that prevents safe surgery or delivery of SBRT Subjects must not be pregnant or breast feeding. Refer to section 4.4 for further detail.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Joshua Meyer, MD
Organizational Affiliation
Fox Chase Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Local Consolidative Therapy in Colorectal Cancer

We'll reach out to this number within 24 hrs